China launches innovative drug for Alzheimer's disease

December 29, the Shanghai Institute of Pharmaceutical Research of the Chinese Academy of Sciences hosted the 9th Phase 1 Global Strategy Launch and the first Cerebral Axis Forum held in Beijing. Shanghai Green Valley Pharmaceutical Co., Ltd. announced that China's original treatment of mild to moderate Alzheimer's disease new drug Ganlut sodium capsule (nine phase one) officially listed in China. At the same time, the future is proposed to invest 3 billion U.S. dollars to support real-world research after the drug's launch, international multi-center phase 3 clinical research "green memory", expand the adaptive evidence research and mechanism in-depth research.November 2 this year, ganlute sodium capsules were approved by the National Drug Administration to improve cognitive function in patients with mild to moderate Alzheimer's disease. The State Drug Administration requested that research on pharmacological mechanisms and long-term safety ability continue after listing, improve the analysis method of oligosaccharin, and submit relevant test data on time.it is understood that the International Multi-Center Phase 3 clinical study will further verify the clinical value of the drug by conducting 12-month double-blind trials and 6-month open trials in 200 clinical centers in North America, the European Union, Eastern Europe, Asia-Pacific and other regions, targeting more than 2,000 patients with mild and moderate Alzheimer's disease. Green Valley said it plans to complete an international multi-center clinical trial by 2024 and aim to complete a global registration of new drugs by 2025.phase 3 clinical study at the International Multi-Center for Drugs was led and chaired by Professor Jeffrey Cummings, director of the Luluvo Center for Brain Health at Cleveland Medical Center in the United States.
(
Health
)